<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8194">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03000270</url>
  </required_header>
  <id_info>
    <org_study_id>DTU</org_study_id>
    <nct_id>NCT03000270</nct_id>
  </id_info>
  <brief_title>Door To Unloading With IMPELLA CP System in Acute Myocardial Infarction</brief_title>
  <acronym>DTU</acronym>
  <official_title>Door To Unloading With IMPELLA CP System in Acute Myocardial Infarction to Reduce Infarct Size (DTU): A Prospective Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abiomed Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abiomed Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Direct active unloading of the left ventricle with the Impella CP System prior to PPCI in
      patients with ST-elevation myocardial infarction (STEMI) is safe and feasible
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center, prospective, randomized, two-arm feasibility trial to assess the potential
      role of unloading with the Impella CP prior to revascularization in reducing infarct size.
      The study design includes 1:1 randomization between: 1) Delay Arm: 30 minutes of unloading
      with Impella CP prior to primary percutaneous coronary intervention (PPCI); and 2) Immediate
      Arm: initiation of Impella CP unloading followed immediately by PPCI.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct size at 30 Days</measure>
    <time_frame>30 Days</time_frame>
    <description>Assessment of Infarct size as a percent of left ventricular mass, evaluated using CMR, at 30 days post PPCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Infarct Size as a % of LV Mass</measure>
    <time_frame>3 - 5 and 30 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of major adverse cardiovascular and cerebral vascular events as assessed by Clinical Events Committee</measure>
    <time_frame>30 Day</time_frame>
    <description>All cause mortality cardiovascular mortality reinfarction, stroke/TIA, vascular complication, worsening heart failure or hemodynamic compromise requiring inotropic or hemodynamic support, repeat revascularization, aortic valve injury or dysfunction, renal failure, hemolysis, hematoma, bleeding, thromboycytopenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Infarct Size as a % of Area (Myocardium) at risk</measure>
    <time_frame>3 - 5 and 30 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy:Left ventricular end systolic volume index (LVESVi)</measure>
    <time_frame>3 - 5 and 30 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Left ventricular end diastolic volume index (LVEDVi)</measure>
    <time_frame>3 - 5 and 30 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Ejection Fraction (EF)</measure>
    <time_frame>3 - 5 and 30 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percent microvascular obstruction (%MVO)</measure>
    <time_frame>3 - 5 and 30 Day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>Prolonged unloading prior to PPCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Activation of Impella CP for a 30 minute duration prior to primary percutaneous coronary intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate unloading prior to PPCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Activation of Impella CP immediately prior to primary percutaneous coronary intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Impella unloading prior to PPCI</intervention_name>
    <description>Impella unloading prior to PPCI</description>
    <arm_group_label>Prolonged unloading prior to PPCI</arm_group_label>
    <arm_group_label>Immediate unloading prior to PPCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Age 21-80 years

          -  First myocardial infarction

          -  Acute anterior STEMI with ≥ 2 mm in 2 or more contiguous anterior leads or≥ 4 mm
             total ST-segment deviation sum in the anterior leads

          -  Signed Informed Consent

        Main Exclusion Criteria:

          -  Cardiogenic shock defined as: systemic hypotension (systolic BP less than 90 mmHg or
             the need for inotropes/pressors to maintain a systolic BP Greater than 90mmHg) plus
             one of the following: any requirement for pressors/inotropes prior to arrival at the
             cath lab, clinical evidence of end organ hypoperfusion, lactate level greater than
             2.5mmol/L

          -  Inferior STEMI or suspected right ventricular failure

          -  Suspected or known pregnancy

          -  Suspected active infection

          -  History or known hepatic insufficiency prior to catheterization

          -  On dialysis therapy

          -  Known contraindication to:

          -  Undergoing MRI or use of gadolinium

          -  Heparin, pork, pork products or contrast media

          -  Receiving a drug-eluting stent

          -  Participation in the active treatment or follow-up phase of another clinical study of
             an investigational drug or device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jenifer Foss</last_name>
    <phone>978-882-8158</phone>
    <email>jfoss@abiomed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellen A Robidoux</last_name>
    <phone>978-646-1663</phone>
    <email>erobidoux@abiomed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ABIOMED, Inc.</name>
      <address>
        <city>Danvers</city>
        <state>Massachusetts</state>
        <zip>01923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jenifer Foss</last_name>
      <phone>978-882-8158</phone>
      <email>jfoss@abiomed.com</email>
    </contact>
    <contact_backup>
      <last_name>Ellen A. Robidoux, BA</last_name>
      <phone>978-646-1663</phone>
      <email>erobidoux@abiomed.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 21, 2016</lastchanged_date>
  <firstreceived_date>December 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infarct Size</keyword>
  <keyword>Impella</keyword>
  <keyword>Unloading</keyword>
  <keyword>Left Ventricle</keyword>
  <keyword>PPCI</keyword>
  <keyword>STEMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
